Carregant...
(177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy
PURPOSE: To develop a prostate-specific membrane antigen (PSMA)-targeted radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized efficacy and minimized toxicity employing the β-particle radiation of (177)Lu. METHODS: We synthesized 14 new PSMA-targeted, (177)Lu-la...
Guardat en:
| Publicat a: | Eur J Nucl Med Mol Imaging |
|---|---|
| Autors principals: | , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8068522/ https://ncbi.nlm.nih.gov/pubmed/31399803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04434-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|